Tego Science
테고사이언스 · 191420
Health Care Pharmaceuticals · KOSDAQ
Market cap US$49.1M (₩67.8B)
Overview
Tego Science develops and supplies cell therapy products, treatments that use living cells to address conditions such as burns, foot ulcers, skin wrinkles, and tendon injuries at a biological level.
Its approved products are used in clinical and hospital settings in South Korea, and it also provides contract development, manufacturing, and quality-testing services to other cell-therapy developers. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds multiple cell-therapy approvals from Korea's drug regulator and operates its own GMP-certified manufacturing facility, making contract services a growing part of its business alongside its own products.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$5.6M
- FY2024US$4.9M
- FY2025US$4.3M
Operating profit
- FY2023−US$860.8K
- FY2024−US$1.6M
- FY2025−US$3.2M
Net income
- FY2023−US$1.7M
- FY2024US$2.4M
- FY2025−US$5.1M
Key ratios (FY2025)
Why it matters
The company holds regulatory approval for three cell-therapy products covering five indications from Korea's Ministry of Food and Drug Safety, a relatively rare position in the domestic market.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?